OX40/TNFRSF4, Mouse, 重组蛋白 (hFc) TMPY-02368

Product Introduction
Bioactivity


英文名: OX40/TNFRSF4 Protein, Mouse, Recombinant (hFc)

描述: OX40 (CD134) and its binding partner, OX40L (CD252), are members of the tumor necrosis factor receptor/tumor necrosis factor superfamily, is known to break an existing state of tolerance in malignancies, leading to a reactivation of antitumor immunity. The interaction between OX40 and OX40L plays an important role in antigen-specific T-cell expansion and survival. OX40 and OX40L also regulate cytokine production from T cells, antigen-presenting cells, natural killer cells, and natural killer T cells, and modulate cytokine receptor signaling. In line with these important modulatory functions, OX40-OX40L interactions have been found to play a central role in the development of multiple inflammatory and autoimmune diseases, making them attractive candidates for intervention in the clinic. Conversely, stimulating OX40 has shown it to be a candidate for therapeutic immunization strategies for cancer and infectious disease.Cancer ImmunotherapyCo-stimulatory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy

存储条件: Lyophilized powder: -20~-80°C for 1 year | Solution: -80°C for 6~12 month

关键字: ACT 35 | CD 134 | ACT-35 | CD-134

OX40/TNFRSF4, Mouse, 重组蛋白 (hFc) TMPY-02368信息由TargetMol中国为您提供，如您想了解更多关于OX40/TNFRSF4, Mouse, 重组蛋白 (hFc) TMPY-02368报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途